Endrina, Alphamer .

HRN: 27-05-46  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/30/2025
AMPICILLIN 250MG (VIAL)
04/30/2025
05/07/2025
IV
35mg
Q6h
Intestinal Amoebiasis
Waiting Final Action 
04/30/2025
GENTAMICIN 40MG/ML, 2ML (AMP)
04/30/2025
05/07/2025
IV
20mg
Q24
Intestinal Amoebiasis
Waiting Final Action 
04/30/2025
METRONIDAZOLE 125MG/5ML, 60ML (BOT)
04/30/2025
05/09/2025
PO
1.2ml
TID
AGE
Waiting Final Action 
05/02/2025
NYSTATIN 100,000IU/ML, 30ML SUSPENSION (BOT)
05/02/2025
05/08/2025
PO
1ml
QID
Mouth Ulcer
Waiting Final Action 
05/02/2025
CEFTRIAXONE 1G (VIAL)
05/02/2025
05/08/2025
IV DRIP
460mg
Q24
Intestinal Parasitism
Waiting Final Action 
05/03/2025
MEBENDAZOLE 100MG/5ML, 60ML SUSPENSION
05/03/2025
05/10/2025
PO
2.5ml
BID
Intestinal Parasitism
Waiting Final Action 
05/05/2025
CLINDAMYCIN 150MG/ML, 4ML (AMP)
05/05/2025
05/11/2025
IV
35mg
Q6h
Sepsis
Waiting Final Action 
05/05/2025
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
05/05/2025
05/11/2025
IV
200mg
Q6h
Sepsis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: